| Autor: |
Nguyen TTT; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Gao Q; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Mun JY; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Zhu Z; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Shu C; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Naim A; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Rogava M; Division of Hematology/Oncology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA., Izar B; Division of Hematology/Oncology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA., Westhoff MA; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 89081 Ulm, Germany., Karpel-Massler G; Department of Neurosurgery, Ulm University Medical Center, 89081 Ulm, Germany., Siegelin MD; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA. |
| Abstrakt: |
Immunotherapies have shown significant promise as an impactful strategy in cancer treatment. However, in glioblastoma multiforme (GBM), the most prevalent primary brain tumor in adults, these therapies have demonstrated lower efficacy than initially anticipated. Consequently, there is an urgent need for strategies to enhance the effectiveness of immune treatments. AURKA has been identified as a potential drug target for GBM treatment. An analysis of the GBM cell transcriptome following AURKA inhibition revealed a potential influence on the immune system. Our research revealed that AURKA influenced PD-L1 levels in various GBM model systems in vitro and in vivo. Disrupting AURKA function genetically led to reduced PD-L1 levels and increased MHC-I expression in both established and patient-derived xenograft GBM cultures. This process involved both transcriptional and non-transcriptional pathways, partly implicating GSK3β. Interfering with AURKA also enhanced NK-cell-mediated elimination of GBM by reducing PD-L1 expression, as evidenced in rescue experiments. Furthermore, using a mouse model that mimics GBM with patient-derived cells demonstrated that Alisertib decreased PD-L1 expression in living organisms. Combination therapy involving anti-PD-1 treatment and Alisertib significantly prolonged overall survival compared to vehicle treatment. These findings suggest that targeting AURKA could have therapeutic implications for modulating the immune environment within GBM cells. |
